TP53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected Osteosarcoma


Osteosarcoma is a rare and highly malignant tumor that usually affects adolescents and young adults. Despite current management protocols, up to half of patients succumb to the disease. Moreover, there is no well-characterized molecular marker for diagnosis and prognosis. TP53 alterations have been associated with a poor prognosis in many cancers. The aim of this retrospective work was to find out whether TP53 functional status predicts response to neoadjuvant chemotherapy and thus may help treatment decision for osteosarcoma patients. Seventeen biopsies of osteosarcoma patients receiving primary metotrexate, cisplatin and adryamicin chemotherapy followed by surgery were analyzed. TP53 exons 5-9 mutations were screened. Among 17 biopsies, 4 (23.5%) displayed TP53 mutations: 3 deletions and one single-nucleotide substitution. The presence of TP53 gene mutation does not correlate with resistance to chemotherapy according to histological Rosen grade and nevertheless is associated with patient’s age in a significant manner (p < 0.05). The presence of non-mutated TP53 is not entirely specific for a good prognosis. We found no evidence that TP53 mutations predict chemoresistance in osteosarcoma patients more over the overall survival curve, followed for more than 12 years, showing no difference between patients with tumors harboring wild type or mutated TP53 gene (p < 0.5). Further analysis to identify other genes that can influence chemotherapy response and clinical outcome in osteosarcoma is needed to improve patient treatment.

Share and Cite:

L. Richter, M. Buzzi and C. Dantas-Barbosa, "TP53 Mutations and Chemotherapy Response to Neoadjuvant Metotrexate, Cisplatin and Adryamicin Chemotherapy in Resected Osteosarcoma," International Journal of Clinical Medicine, Vol. 4 No. 12A, 2013, pp. 44-50. doi: 10.4236/ijcm.2013.412A1008.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Dorfman, H.D. and Czerniak, B. (1995) Bone cancers. Cancer, 75, 203-210.<203::AID-CNCR2820751308>3.0.CO;2-V
[2] Dahlin, D.C. and Unni, K.K. (1977) Osteosarcoma of bone and its important recognizable varieties. The American Journal of Surgical Pathology, 1, 61-72.
[3] Marina, N., Gebhardt, M., Teot, L. and Gorlick, R. (2004) Biology and therapeutic advances for pediatric osteosarcoma. The Oncologist, 9, 422-441.
[4] Group, E.G.W. and Saeter, G. (2007) Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology/ESMO, 18, ii77-78.
[5] Simons, A., Schepens, M., Forus, A., Godager, L., van Asseldonk, M., Myklebost, O., et al. (1999) A novel chromosomal region of allelic loss, 4q32-q34, in human osteosarcomas revealed by representational difference analysis. Genes, Chromosomes & Cancer, 26, 115-124.<115::AID-GCC3>3.0.CO;2-E
[6] Baker, S.J., Markowitz, S., Fearon, E.R., Willson, J.K. and Vogelstein, B. (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912-915.
[7] Ozaki, T. and Nakagawara, A. (2011) p53: The attractive tumor suppressor in the cancer research field. Journal of Biomedicine & Biotechnology, 2011, 603925.
[8] Vousden, K.H. and Lu, X. (2002) Live or let die: The cell’s response to p53. Nature reviews. Cancer, 2, 594-604.
[9] Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P., et al. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: Lessons from recent developments in the IARC TP53 database. Human Mutation, 28, 622-629.
[10] Olivier, M., Goldgar, D.E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. and Eeles, R.A. (2003) Li-Fraumeni and related syndromes: Correlation between tumor type, family structure, and TP53 genotype. Cancer Research, 63, 6643-6650.
[11] Staples, O.D., Steele, R.J. and Lain, S. (2008) p53 as a therapeutic target. The Surgeon: Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 6, 240-243.
[12] Vousden, K.H. and Lane, D.P. (2007) p53 in health and disease. Nature reviews. Molecular Cell Biology, 8, 275-283.
[13] Staib, F., Robles, A.I., Varticovski, L., Wang, X.W., Zeeberg, B.R., Sirotin, M., et al. (2005) The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Research, 65, 10255-10264.
[14] Olivier, M., Langerod, A., Carrieri, P., Bergh, J., Klaar, S., Eyfjord, J., et al. (2006) The clinical value of somatic TP53 gene mutations in 1794 patients with breast cancer. Clinical Cancer Research, 12, 1157-1167.
[15] Perrone, F., Bossi, P., Cortelazzi, B., Locati, L., Quattrone, P., Pierotti, M.A., et al. (2010) TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 28, 761-766.
[16] Picci, P., Bacci, G., Campanacci, M., Gasparini, M., Pilotti, S., Cerasoli, S., et al. (1985) Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer, 56, 1515-1521.<1515::AID-CNCR2820560707>3.0.CO;2-6
[17] Kurvinen, K., Hietanen, S., Syrjanen, K. and Syrjanen, S. (1995) Rapid and effective detection of mutations in the p53 gene using nonradioactive single-strand conformation polymorphism (SSCP) technique applied on PhastSystem. Journal of Virological Methods, 51, 43-53.
[18] Masuda, H., Miller, C., Koeffler, H.P., Battifora, H. and Cline, M.J. (1987) Rearrangement of the p53 gene in human osteogenic sarcomas. Proceedings of the National Academy of Sciences of the United States of America, 84, 7716-7719.
[19] Orita, M., Iwahana, H., Kanazawa, H., Hayashi, K. and Sekiya, T. (1989) Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proceedings of the National Academy of Sciences of the United States of America, 86, 2766-2770.
[20] Goto, A., Kanda, H., Ishikawa, Y., Matsumoto, S., Kawaguchi, N., Machinami, R., et al. (1998) Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Japanese Journal of Cancer Research: Gann, 89, 539-547.
[21] Rosen, G., Loren, G.J., Brien, E.W., Ramana, L., Waxman, A., Lowenbraun, S., et al. (1993) Serial thallium-201 scintigraphy in osteosarcoma. Correlation with tumor necrosis after preoperative chemotherapy. Clinical Orthopaedics and Related Research, 293, 302-306.
[22] Radig, K., Schneider-Stock, R., Oda, Y., Neumann, W., Mittler, U. and Roessner, A. (1996) Mutation spectrum of p53 gene in highly malignant human osteosarcomas. General & Diagnostic Pathology, 142, 25-32.
[23] Gokgoz, N., Wunder, J.S., Mousses, S., Eskandarian, S., Bell, R.S. and Andrulis, I.L. (2001) Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma. Cancer, 92, 2181-2189.<2181::AID-CNCR1561>3.0.CO;2-3
[24] Tsuchiya, T., Sekine, K., Hinohara, S., Namiki, T., Nobori, T. and Kaneko, Y. (2000) Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma. Cancer Genetics and Cytogenetics, 120, 91-98.
[25] Patino-Garcia, A. and Sierrasesumaga, L. (1997) Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients. Cancer Genetics and Cytogenetics, 98, 50-55.
[26] Lonardo, F., Ueda, T., Huvos, A.G., Healey, J. and Ladanyi, M. (1997) p53 and MDM2 alterations in osteosarcomas: Correlation with clinicopathologic features and proliferative rate. Cancer, 79, 1541-1547.<1541::AID-CNCR15>3.0.CO;2-Y
[27] Wunder, J.S., Gokgoz, N., Parkes, R., Bull, S.B., Eskandarian, S., Davis, A.M., et al. (2005) TP53 mutations and outcome in osteosarcoma: A prospective, multicenter study. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 23, 1483-1490.
[28] Hu, X., Yu, A.X., Qi, B.W., Fu, T., Wu, G., Zhou, M., et al. (2010) The expression and significance of IDH1 and p53 in osteosarcoma. Journal of Experimental & Clinical Cancer Research: CR, 29, 43.
[29] Stephens, P.J., Greenman, C.D., Fu, B., Yang, F., Bignell, G.R., Mudie, L.J., et al. (2011) Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell, 144, 27-40.
[30] Chang, T.C., Wentzel, E.A., Kent, O.A., Ramachandran, K., Mullendore, M., Lee, K.H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C.J., et al. (2007) Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Molecular Cell, 26, 745-752.
[31] He, L., He, X., Lim, L.P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) A microRNA component of the p53 tumour suppressor network. Nature, 447, 1130-1134.
[32] Le, M.T., The, C., Shyh-Chang, N., Xie, H., Zhou, B., Korzh, V., Lodish, H.F. and Lim, B. (2009) Micro-RNA-125b is a novel negative regulator of p53. Genes & Development, 23, 862-876.
[33] Bourdon, J.C., Fernandes, K., Murray-Zmijewski, F., Liu, G., Diot, A., Xirodimas, D.P., Saville, M.K. and Lane, D.P. (2005) p53 isoforms can regulate p53 transcriptional activity. Genes & Development, 19, 2122-2137.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.